Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Iron deficiency is common in kidney transplant recipients and is associated with impaired
exercise tolerance and an unfavourable prognosis.
This multicentre double-blind, placebo-controlled randomized controlled clinical trial will
allow the investigators to analyse the effects of intravenous iron correction with
ferric(III) carboxymaltose on exercise tolerance and other parameters, in comparison to a
placebo.
Phase:
Phase 3
Details
Lead Sponsor:
University Medical Center Groningen
Collaborators:
Dutch Kidney Foundation Vifor Fresenius Medical Care Renal Pharma